Evaluation of the effect of Latanaprost in the treatment of androgenetic alopecia

Phase 3

Recruiting

• Conditions: Androgenic alopecia.; Androgenic alopecia, unspecified; L64.9

• Registration Number: IRCT20211228053553N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 50

Inclusion Criteria

Satisfaction of the patient and his family to participate in the study
Confirmation of androgenetic alopecia by two experienced dermatologists based on Hamilton diagnostic criteria
Age 18 to 45 years
2 to 5 hair loss severity according to Hamilton criteria
The duration of hair loss is less than 10 years

Exclusion Criteria

History or observation of allergies to any of the drugs Minoxidil and Latanoprost, history of heart disease and use of antihypertensive drugs Receiving systemic treatment for androgenic alopecia during the 6 months before the study of other types of alopecia such as alopecia areata, telogen effluvium, anagen effluvium scarring alopecia, any systemic skin disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of hair loss. Timepoint: Before and after the intervention. Method of measurement: By a skilled physician based on Hamilton-Norwood for male pattern hair loss.